Ozempic's Kidney Trial Success Sends Dialysis Stocks Plummeting
TL;DR
Kidney-dialysis stocks, including Fresenius Medical Care and DaVita, experienced significant declines after Novo Nordisk announced that its diabetes drug Ozempic showed potential in delaying the progression of kidney disease. Frankfurt-listed shares in Fresenius Medical Care fell nearly 8%, while the company's American depositary receipts dropped 17%. Similarly, stock in U.S.-listed DaVita crashed 17%.
Topics:top-newsbusiness#business#dialysis-stocks#fresenius-medical-care#kidney-trial#novo-nordisk#ozempic
- Ozempic Kidney Trial Sinks Dialysis Stocks The Wall Street Journal
- Novo Nordisk stops Ozempic kidney trial after early signs of success Reuters
- Ozempic's early success in kidney disease trial drags on dialysis stocks Yahoo Finance
- Novo Nordisk knocks out Fresenius, DaVita and Baxter Marketscreener.com
- Obesity revolution gorges on dialysis maker Reuters
Want the full story? Read the original reporting
Read on The Wall Street Journal